Centrexion Therapeutics Announces CNTX-4975 and CNTX-6970 Clinical Data Presentations at the 34th Annual American Academy of Pain Medicine Meeting

BOSTON, Mass., April 19, 2018 – Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced it will present Phase 1 safety and tolerability data of single ascending doses of CNTX-6970 in healthy
volunteers and Phase 2b efficacy and safety data of CNTX-4975 for the treatment of moderate to severe osteoarthritis knee pain at the 34th Annual American Academy of Pain Medicine (AAPM) Meeting taking place April 25 – 29, 2018 at the Vancouver Convention Center in Vancouver, Canada.

This entry was posted in Recent Development News: Q2 - 2018, Recent Developments. Bookmark the permalink.
Read Full Article »